Rôla, 2022 - Google Patents
Comparative efficacy analysis of whole-sporozoite vaccines against MalariaRôla, 2022
View PDF- Document ID
- 15014809984148675737
- Author
- Rôla C
- Publication year
External Links
Snippet
Malaria is a deadly mosquito-borne infectious disease caused by Plasmodium parasites, for which the only licensed vaccine provides modest, rapidly waning protection. Whole- sporozoite (WSp) pre-erythrocytic vaccines constitute a potential solution for inducing long …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Basso | Modulation of immune response in experimental Chagas disease | |
| BR112018076633A2 (en) | recombinant asfv-g mutant (african swine fever virus isolate georgia 2007), cdna mutant, vaccine composition, method for the protection of pigs against swine fever virus isolate georgia 2007 (asfv-g), method for differentiate a vaccinated mammal with a live attenuated vaccine asfv-g - 9gl / - uk | |
| Hafalla et al. | Protective and pathogenic roles of CD8+ T cells during malaria infection | |
| Andryukov et al. | Older adults: panoramic view on the COVID-19 vaccination | |
| MacDonald et al. | Tuberculosis Vaccine Development—Its History and Future Directions | |
| Bassi et al. | Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice | |
| Escribano-Romero et al. | Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE) | |
| Calvo-Pinilla et al. | Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge | |
| Shebl et al. | Staphylococcus aureus derived hyaluronic acid and bacillus Calmette-Guérin purified proteins as immune enhancers to rabies vaccine and related immuno-histopathological alterations | |
| Doyle et al. | Immune correlates of protection following Rift Valley fever virus vaccination | |
| Rôla | Comparative efficacy analysis of whole-sporozoite vaccines against Malaria | |
| Watson et al. | Cryopreserved sporozoites with and without the glycolipid adjuvant 7DW8-5 protect in prime-and-trap malaria vaccination | |
| Rashi | The moral and religious obligation to vaccinate children in Jewish ethics | |
| Flaxman et al. | Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse | |
| Chen et al. | Shigella vaccine development: finding the path of least resistance | |
| Luna et al. | Vaccine development against neglected tropical diseases | |
| Zumla et al. | Vaccine against Middle East respiratory syndrome coronavirus | |
| Parmar et al. | Route of administration of attenuated sporozoites is instrumental in rendering immunity against Plasmodia infection | |
| Syaifudin et al. | Effectiveness of gamma rays in attenuating rodent malaria parasites of Plasmodium berghei in blood of mice | |
| Cohn et al. | Mining for crypto protection: a search for Cryptosporidium antibodies reveals antigens associated with immunity | |
| Zhang et al. | Booster vaccination with live attenuated Vibrio anguillarum elicits strong protection despite weak specific antibody response in zebrafish | |
| Mutiso et al. | Safety and skin delayed-type hypersensitivity response in vervet monkeys immunized with Leishmania donovani sonicate antigen delivered with adjuvants | |
| Fernandes | Internship Reports and Monography entitled “Whole-sporozoite vaccines against malaria: Current approaches and future prospects based on genetically modified Plasmodium berghei sporozoites” | |
| White | Models for measuring and predicting malaria vaccine efficacy | |
| Beaver | Zika virus induced neuro-ocular pathology correlates with autoreactive anti-ganglioside antibodies and can be ameliorated with cutaneous vaccination |